Skip to main content

Advertisement

Table 2 Population at risk (N), incident cases, incidence rate and IRR, by medicine and rofecoxib user status, for ALSWH Older cohort

From: An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

  Continuous Users Non-Continuous Users IRR (95% CI)
Medicine Na Cases Incidence rate (per 100,000 person days) Na Cases Incidence rate (per 100,000 person days)  
COX-2s Overall 163 130 272.2 320 146 58.8 4.6 (3.6,5.9)
Celecoxib 163 59 44.9 320 54 16.7 2.7 (1.8,4)
Lumiracoxib 163 12 6.7 320 17 4.7 1.4 (0.6,3.2)
Meloxicam 163 98 111.3 320 100 34.8 3.2 (2.4,4.3)
ns-NSAIDs Overall 137 56 47.9 274 101 40.7 1.2 (0.8,1.6)
Diclofenac 137 14 9.6 274 24 8.0 1.2 (0.6,2.4)
Ibuprofen 137 10 6.6 274 15 4.9 1.4 (0.5,3.2)
Naproxen 137 10 6.6 274 8 2.6 2.6 (0.9,7.5)
Piroxicam 137 43 33.2 274 95 37.9 0.9 (0.6,1.3)
Acetylsalicylic acid 137 4 2.6 274 3 1.0 2.7 (0.5,18.4)
Other ns-NSAIDs 137 5 3.2 274 9 2.9 1.1 (0.3,3.7)
Opioids Overall 143 45 32.5 321 86 26.7 1.2 (0.8,1.8)
Buprenorphine 143 5 3.0 321 12 3.2 0.9 (0.3,2.9)
Morphine 143 5 3.0 321 19 5.1 0.6 (0.2,1.6)
Oxycodone 143 15 9.3 321 33 9.2 1 (0.5,1.9)
Tramadol 143 36 25.5 321 52 15.5 1.7 (1,2.6)
Other Opioids 143 2 1.2 321 4 1.1 1.1 (0.1,7.9)
Paracetamol Overall 71 56 138.0 171 96 76.6 1.8 (1.3,2.5)
Paracetamol and combinations excl. psycholeptics 71 56 138.0 171 96 76.4 1.8 (1.3,2.5)
Codeine, combinations excl. psycholeptics 71 3 3.7 171 6 3.1 1.2 (0.2,5.6)
  1. a Includes only women not dispensed these medicines in the 12 months prior to rofecoxib withdrawal